Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
All content for On The Pen With Dave Knapp is the property of Bleav, Dave Knapp Founder of On The Pen and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
TRUMP: Ozempic Will Soon be $150 in the US! Meet the Reporter Who Made Him Say It!
On The Pen With Dave Knapp
29 minutes 33 seconds
2 weeks ago
TRUMP: Ozempic Will Soon be $150 in the US! Meet the Reporter Who Made Him Say It!
Joining me today is Max Beyer, pharma reporter at Endpoints News and one of the sharpest voices covering pharma policy, pricing, and the biotech world. If you’ve seen the viral clip from Trump’s press event where he promised to drop the price of the so-called ‘fat shot’ to $150, that moment started with Max’s question. His work at Endpoints has been ahead of the curve on everything from Most Favored Nation drug pricing to the political tug-of-war that’s shaping the future of GLP-1 access in America.
Max isn’t just writing about the drug industry, he’s talking to the people moving it, and today, we get to hear what it was like to be in the room when a single question shook the global obesity market.
On The Pen With Dave Knapp
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
